1. Market Research
  2. > Tobacco Market Trends
  3. > Japan Tobacco Inc. - Product Pipeline Review - 2014

Japan Tobacco Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 49 pages

Japan Tobacco Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Japan Tobacco Inc. - Product Pipeline Review - 2014’, provides an overview of the Japan Tobacco Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Japan Tobacco Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Japan Tobacco Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Japan Tobacco Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Japan Tobacco Inc.’s pipeline products

Reasons to buy

- Evaluate Japan Tobacco Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Japan Tobacco Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Japan Tobacco Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Japan Tobacco Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Japan Tobacco Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Japan Tobacco Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Japan Tobacco Inc. - Product Pipeline Review - 2014
Table of Contents
Japan Tobacco Inc. Snapshot 6
Japan Tobacco Inc. Overview 6
Key Information 6
Key Facts 6
Japan Tobacco Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Japan Tobacco Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Japan Tobacco Inc. - Pipeline Products Glance 17
Japan Tobacco Inc. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Japan Tobacco Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Japan Tobacco Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Japan Tobacco Inc. - Drug Profiles 21
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
TO-206 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
JTT-851 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
JTZ-951 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
JTE-051 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
JTE-052 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
JTK-351 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
JTT-251 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
JTT-252 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
OR-1050 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Vaccine for Cedar Pollen Allergy 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Japan Tobacco Inc. - Pipeline Analysis 33
Japan Tobacco Inc. - Pipeline Products by Target 33
Japan Tobacco Inc. - Pipeline Products by Route of Administration 34
Japan Tobacco Inc. - Pipeline Products by Molecule Type 35
Japan Tobacco Inc. - Pipeline Products by Mechanism of Action 36
Japan Tobacco Inc. - Recent Pipeline Updates 37
Japan Tobacco Inc. - Dormant Projects 40
Japan Tobacco Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
JTK-652 41
JTT-553 41
JTV-803 41
dalcetrapib 42
elvitegravir 42
encaleret 42
granotapide 42
JTE-607 42
JTK-003 42
JTK-656 42
JTK-853 42
JTS-653 43
JTT-302 43
JTT-551 43
JTT-552 43
JTT-651 43
JTT-654 43
MEDI-570 43
Japan Tobacco Inc. - Company Statement 44
Japan Tobacco Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations and Subsidiaries 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables

Japan Tobacco Inc., Key Information 6
Japan Tobacco Inc., Key Facts 6
Japan Tobacco Inc. - Pipeline by Indication, 2014 9
Japan Tobacco Inc. - Pipeline by Stage of Development, 2014 10
Japan Tobacco Inc. - Monotherapy Products in Pipeline, 2014 11
Japan Tobacco Inc. - Combination Treatment Modalities in Pipeline, 2014 12
Japan Tobacco Inc. - Partnered Products in Pipeline, 2014 13
Japan Tobacco Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Japan Tobacco Inc. - Out-Licensed Products in Pipeline, 2014 15
Japan Tobacco Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16
Japan Tobacco Inc. - Phase III, 2014 17
Japan Tobacco Inc. - Phase II, 2014 18
Japan Tobacco Inc. - Phase I, 2014 19
Japan Tobacco Inc. - Preclinical, 2014 20
Japan Tobacco Inc. - Pipeline by Target, 2014 33
Japan Tobacco Inc. - Pipeline by Route of Administration, 2014 34
Japan Tobacco Inc. - Pipeline by Molecule Type, 2014 35
Japan Tobacco Inc. - Pipeline Products by Mechanism of Action, 2014 36
Japan Tobacco Inc. - Recent Pipeline Updates, 2014 37
Japan Tobacco Inc. - Dormant Developmental Projects,2014 40
Japan Tobacco Inc. - Discontinued Pipeline Products, 2014 41
Japan Tobacco Inc., Subsidiaries 46

List of Figures

Japan Tobacco Inc. - Pipeline by Top 10 Indication, 2014 8
Japan Tobacco Inc. - Pipeline by Stage of Development, 2014 10
Japan Tobacco Inc. - Monotherapy Products in Pipeline, 2014 11
Japan Tobacco Inc. - Partnered Products in Pipeline, 2014 13
Japan Tobacco Inc. - Out-Licensed Products in Pipeline, 2014 15
Japan Tobacco Inc. - Pipeline by Top 10 Target, 2014 33
Japan Tobacco Inc. - Pipeline by Top 10 Route of Administration, 2014 34
Japan Tobacco Inc. - Pipeline by Top 10 Molecule Type, 2014 35
Japan Tobacco Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Japan Tobacco Inc. (2914) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Japan Tobacco Inc. (2914) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • August 2016
  • by Global Data

Summary Japan Tobacco Inc. (JT Group) is a tobacco company that manufactures and sells tobacco products, primarily cigarettes. It also manufactures, markets and sells varied pharmaceutical and processed ...

Universal Corporation - Strategy, SWOT and Corporate Finance Report

Universal Corporation - Strategy, SWOT and Corporate Finance Report

  • $ 175
  • Company report
  • October 2016
  • by MarketLine

Summary Universal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, ...

Alliance One International, Inc. - Strategy, SWOT and Corporate Finance Report

Alliance One International, Inc. - Strategy, SWOT and Corporate Finance Report

  • $ 175
  • Company report
  • October 2016
  • by MarketLine

Summary Alliance One International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.